This study focuses on patients with Newly Diagnosed Multiple Myeloma who have undergone Autologous Stem Cell Transplantation. The research examines three different treatment approaches as maintenance therapy: teclistamab combined with lenalidomide, teclistamab alone, and lenalidomide alone. Multiple myeloma is a type of blood cancer that affects plasma cells, which are responsible for producing antibodies to fight infections.
The study aims to compare how well these treatments work in preventing the cancer from returning after stem cell transplantation. Teclistamab is given as an injection under the skin, while lenalidomide is taken as capsules by mouth. The treatment continues for up to 24 months, depending on how well patients respond and any side effects they may experience.
During the study, patients will receive regular medical check-ups to monitor their health status and response to treatment. The effectiveness of the treatments will be measured by how long patients remain free of disease progression and whether they achieve a complete response to therapy. Patients will also be monitored for any side effects that may occur during treatment.
1Initial assessment
Your eligibility for the study will be evaluated if you have been diagnosed with newly diagnosed multiple myeloma and have completed initial treatment with stem cell transplantation
Laboratory tests and pregnancy tests (if applicable) will be performed to confirm your eligibility
2Treatment assignment
You will be randomly assigned to one of three treatment groups:
Group 1: Teclistamab combined with lenalidomide
Group 2: Teclistamab alone
Group 3: Lenalidomide alone
3Treatment administration
Lenalidomide is taken as hard capsules by mouth in doses of 2.5 mg, 5 mg, 10 mg, or 15 mg
Teclistamab is given as an injection under the skin
Treatment will continue as maintenance therapy following your stem cell transplantation
4Monitoring period
Regular assessments will be performed to evaluate your response to treatment
Blood tests will be conducted to monitor your condition
Your overall health status and any side effects will be tracked throughout the study
5Follow-up period
After completing treatment, you will continue to be monitored for any long-term effects
The study is expected to continue until November 2031
Additional follow-up visits will be scheduled to assess your health status
Who Can Join the Study?
Must be 18 years of age or older and legally able to provide consent
Must have newly diagnosed Multiple Myeloma and received 4-6 cycles of initial therapy
Must have undergone stem cell transplant within the past 12 months from starting initial therapy
Must be within 6 months of last transplant (7 months if received additional therapy)
Must have achieved at least a partial response to previous treatment
Must not have received any maintenance therapy
Must have an ECOG performance status of 0-2 (measure of patient’s ability to perform daily activities)
Must meet required laboratory test values
Must be willing to follow the study’s lifestyle restrictions
For women who can become pregnant:
Must have negative pregnancy tests
Must use two reliable methods of birth control
Must not donate eggs during the study and for specified time after
For men:
Must use condoms during intimate activity
Must not donate sperm during the study and for specified time after
Must sign an informed consent form showing understanding of the study
Who Cannot Join the Study?
Active multiple myeloma that has not responded to initial treatment
History of significant heart problems including:
Heart attack in the past 6 months
Unstable heart rhythm disorders
Severe heart failure
Severe kidney problems requiring dialysis
Active or chronic hepatitis B or C infection
Known active HIV infection
History of other cancers within the past 3 years (except for successfully treated skin cancers or early-stage cancers)
Pregnant or breastfeeding women
Participation in another clinical trial within the past 30 days
Known allergic reactions to similar medications
Serious psychiatric conditions that could interfere with the study
Unable to take blood-thinning medications
Major surgery within 2 weeks before starting the study
Any condition that, in the opinion of the study doctor, would make participation unsafe
Teclistamab is a medication that targets specific proteins on cancer cells to help fight multiple myeloma. It works by helping the body’s immune system recognize and attack cancer cells more effectively.
Lenalidomide is a medication commonly used in multiple myeloma treatment. It works by helping to strengthen the immune system’s response against cancer cells and may also help prevent the growth of new blood vessels that feed tumors.
The trial also includes combinations of these medications:
– Teclistamab combined with Lenalidomide is being studied to see if using both medications together provides better results than using either medication alone
– Teclistamab alone is being compared to Lenalidomide alone to determine which single medication might work better as maintenance therapy after stem cell transplantation
These medications are being studied specifically as maintenance therapy, which means they are given after stem cell transplantation to help keep the cancer from returning.
Multiple Myeloma – A type of blood cancer that develops in plasma cells, which are white blood cells that help fight infections. In this condition, abnormal plasma cells multiply uncontrollably in the bone marrow, forming tumors in multiple bones throughout the body. These cancerous cells produce large amounts of abnormal proteins while preventing the production of normal, healthy blood cells. The disease typically affects bones, leading to their weakening, and can impact the body’s ability to produce normal blood cells. Multiple myeloma often develops gradually, starting from a precancerous condition called monoclonal gammopathy of undetermined significance (MGUS).
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Czechia 
Denmark 
France 
Germany 
Greece 
Ireland 
Italy 
Norway 
Poland 
Portugal 
The Netherlands